A Treatment Option for Patients with Metastatic Squamous NSCLC Who Progressed After Platinum-Based Chemotherapy
This article is sponsored and developed by Boehringer Ingelheim Pharmaceuticals
July 13, 2020|Federal Practitioner
In this supplement to Federal Practitioner,
Dr. Raja Mudad, MD, discusses:
- The burden of squamous non-small cell lung cancer among active United States military and veterans
- Available treatment options for advanced metastatic squamous NSCLC
- Clinical trial data surrounding a treatment for patients with metastatic squamous NSCLC who have progressed after platinum-based chemotherapy, that can be used as early as second-line
(06/20) PC-US-115598